In oncology trials, overall survival (OS) is considered the most reliable and preferred
endpoint to evaluate the benefit of drug treatment. Other relevant variables are also …

Model‐based drug development in oncology is still lagging despite a good momentum in the
clinical pharmacology and pharmacometry community in the past few years. The failure rate …

The predictive value of longitudinal biomarker data (vascular endothelial growth factor
(VEGF), soluble VEGF receptor (sVEGFR)‐2, sVEGFR‐3, and soluble stem cell factor …

Purpose Axitinib, a potent and selective second-generation inhibitor of vascular endothelial
growth factor receptors, has shown activity in advanced thyroid cancer in a Phase II study …

Differentiated thyroid cancer is characteristically associated with an innocuous clinical
course, but a minority of cases may manifest surprisingly aggressive behaviour. Such …

Purpose An integrated population pharmacokinetic (popPK) model was developed to
describe the pharmacokinetics (PK) of tyrosine kinase inhibitor cabozantinib in healthy …

The prospect of precision dosing in oncology is attractive for several reasons. Many
anticancer drugs display narrow therapeutic indices, where suboptimal therapy may lead to …

Introduction: Approaches aiming to model the time course of tumor growth and tumor growth
inhibition following a therapeutic intervention have recently been proposed for supporting …

Purpose: Rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte
growth factor. In a randomized phase II study, trends toward improved survival were …

Motesanib (AMG 706) is a small organic molecule that acts as a multi-targeted tyrosine
kinase inhibitor of VEGF, PDGF and stem cell factor receptor. It exhibits a potent antitumor …